Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.